STAT May 22, 2024
John Wilkerson

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, FDA, Govt Agencies, Patient / Consumer, Trends
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article